Literature DB >> 26969368

Carbamazepine induced Stevens-Johnson syndrome.

Andre B S Khoo1, Faisal R Ali2, Zenas Z N Yiu3, Janice E Ferguson3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26969368      PMCID： PMC4800262          DOI： 10.1136/bcr-2016-214926

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


× No keyword cloud information.
  3 in total

1.  HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.

Authors:  Amy Hui-Ping Khor; Kheng-Seang Lim; Chong-Tin Tan; Su-Ming Wong; Ching-Ching Ng
Journal:  Epilepsia       Date:  2014-09-29       Impact factor: 5.864

2.  Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions.

Authors:  Zhibin Chen; Danny Liew; Patrick Kwan
Journal:  Neurology       Date:  2014-10-29       Impact factor: 9.910

Review 3.  Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.

Authors:  Robert A Schwartz; Patrick H McDonough; Brian W Lee
Journal:  J Am Acad Dermatol       Date:  2013-08       Impact factor: 11.527
  3 in total
  1 in total

1.  The Co-Existence of Agranulocytosis and Stevens-Johnson Syndrome (SJS) in Carbamazepine Therapy: A Case Report.

Authors:  Saima Batool; Diana Voloshyna; Muhammad Usama; Muhammad Suleman; Qudsia I Sandhu; Laxman Nepal; Naglaa G Ghobriel; Jaina Mengar; Ahmed Soodod Mohammed Rasmy
Journal:  Cureus       Date:  2022-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.